Pf Prism Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PF PRISM, and what generic alternatives to PF PRISM drugs are available?
PF PRISM has sixteen approved drugs.
There are twenty-nine US patents protecting PF PRISM drugs.
There are six hundred and twelve patent family members on PF PRISM drugs in sixty-six countries and seventy-two supplementary protection certificates in eighteen countries.
Summary for Pf Prism
International Patents: | 612 |
US Patents: | 29 |
Tradenames: | 11 |
Ingredients: | 11 |
NDAs: | 16 |
Patent Litigation for Pf Prism: | See patent lawsuits for Pf Prism |
Drugs and US Patents for Pf Prism
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pf Prism Cv | XALKORI | crizotinib | CAPSULE, PELLETS;ORAL | 217581-001 | Sep 7, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729-002 | Sep 26, 2023 | RX | Yes | Yes | 7,767,678*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-002 | Jan 27, 2012 | RX | Yes | Yes | 8,791,140 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pf Prism Cv | XALKORI | crizotinib | CAPSULE;ORAL | 202570-002 | Aug 26, 2011 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729-002 | Sep 26, 2023 | RX | Yes | Yes | RE42376*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-003 | Oct 27, 2017 | RX | Yes | No | 7,919,625*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pf Prism Cv | XELJANZ | tofacitinib citrate | TABLET;ORAL | 203214-002 | May 30, 2018 | RX | Yes | Yes | RE41783 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pf Prism
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pf Prism Cv | ZMAX | azithromycin | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 050797-001 | Jun 10, 2005 | 6,984,403 | ⤷ Try a Trial |
Pf Prism Cv | ZMAX | azithromycin | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 050797-001 | Jun 10, 2005 | 7,887,844 | ⤷ Try a Trial |
Pf Prism Cv | VFEND | voriconazole | INJECTABLE;INTRAVENOUS | 021267-001 | May 24, 2002 | 5,773,443 | ⤷ Try a Trial |
Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-001 | Feb 29, 2008 | 7,291,347 | ⤷ Try a Trial |
Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-003 | Feb 23, 2004 | 5,212,155*PED | ⤷ Try a Trial |
Pf Prism Cv | VFEND | voriconazole | TABLET;ORAL | 021266-002 | May 24, 2002 | 5,364,938 | ⤷ Try a Trial |
Pf Prism Cv | XELJANZ | tofacitinib citrate | TABLET;ORAL | 203214-002 | May 30, 2018 | 7,842,699 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PF PRISM drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2018-10-15 |
➤ Subscribe | Tablets | 50 mg and 200 mg | ➤ Subscribe | 2008-04-14 |
➤ Subscribe | For Injection | 50 mg per vial | ➤ Subscribe | 2009-06-15 |
➤ Subscribe | Tablets | 1 mg and 2 mg | ➤ Subscribe | 2009-12-17 |
➤ Subscribe | Extended-release Tablets | 50 mg and 100 mg | ➤ Subscribe | 2012-02-29 |
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-05-10 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Tablets | 100mg and 500mg | ➤ Subscribe | 2016-09-06 |
➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2008-09-12 |
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2010-10-08 |
➤ Subscribe | Injection | 25 mg/mL, 1.8 mL vial | ➤ Subscribe | 2011-05-25 |
➤ Subscribe | Tablets | 0.5 mg | ➤ Subscribe | 2010-08-25 |
➤ Subscribe | Extended-release Tablets | 25 mg | ➤ Subscribe | 2015-05-08 |
➤ Subscribe | Tablets | 1 mg and 5 mg | ➤ Subscribe | 2018-02-23 |
International Patents for Pf Prism Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20090127949 | ⤷ Try a Trial |
Poland | 378759 | ⤷ Try a Trial |
European Patent Office | 1466889 | ⤷ Try a Trial |
Eurasian Patent Organization | 200200120 | ⤷ Try a Trial |
Australia | 2006323027 | ⤷ Try a Trial |
Poland | 355907 | ⤷ Try a Trial |
African Regional IP Organization (ARIPO) | 1486 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pf Prism Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1218348 | CA 2013 00010 | Denmark | ⤷ Try a Trial | |
0648494 | C300055 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: SIROLIMUS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT; NATL. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: CH CH/55243 20000926 |
1786785 | 2013C/021 | Belgium | ⤷ Try a Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), OTHER |
0401747 | 25/2001 | Austria | ⤷ Try a Trial | PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: LI 5524301 20000926 |
1218348 | 122013000016 | Germany | ⤷ Try a Trial | PRODUCT NAME: AXITINIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/12/777/001-006 20120903 |
1786785 | PA2013005 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: CRIZOTINIBUM; REGISTRATION NO/DATE: EU/1/12/793/001 - EU/1/12/793/004 20121023 |
1666481 | 2017C/032 | Belgium | ⤷ Try a Trial | PRODUCT NAME: TOFACITINIB; AUTHORISATION NUMBER AND DATE: EU/1/17/1178 20170324 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.